APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2034 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A				
Initial application — chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant Applications from any specialist. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate) Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection or Patient has chronic hepatitis C and is co-infected with HIV or Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant				
and Maximum of 48 weeks therapy				
Renewal — Chronic hepatitis C - genotype 1 ir				
Current approval Number (if known):	ious disease specialist or general physician. Approva	uls valid for 18 months		
Prerequisites(tick boxes where appropriate)	out discuss specialist of general physician. Approve	to valid for 10 months.		
Patient has chronic hepatitis C, ge	enotype 1			
and Patient has had previous treatment with pegylated interferon and ribavirin and				
Patient has responder relap	esed			
or Patient was a partial respon	nder			
and Patient is to be treated in combina	ation with boceprevir			
Maximum of 48 weeks therapy				

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2034 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A - continued				
	type 1 infection treatment more than 4 years prions disease specialist or general physician. Approva			
and Patient has had previous treatment with pegylated interferon and ribavirin and				
Patient has responder relaps	Patient has responder relapsed			
Patient was a partial respond	esponder			
Patient received interferon tr	eatment prior to 2004			
and Patient is to be treated in combination with boceprevir and Maximum of 48 weeks therapy				
Waximum of 40 weeks therapy				
Initial application — chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV Applications from any specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
Patient has chronic hepatitis C, ger	notype 2 or 3 infection			
Maximum of 6 months therapy				

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2034 August 2025

APPLICAN	IT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:		First Names:	First Names:		
Name:		Surname:	Surname:		
Address:		DOB:	Address:		
		Address:			
Fax Number	er:		Fax Number:		
Pegylate	d Interferon alfa-2A - continued				
Initial application — Hepatitis B Applications only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate)					
and	· ·	infection (HBsAg positive for more than 6 months)			
	Patient is Hepatitis B treatment-na	ive			
and	ALT > 2 times Upper Limit of Norm	nal			
and	HBV DNA < 10 log10 lU/ml				
and					
	HBeAg positive				
	Serum HBV DNA greater the fibrosis)	an or equal to 2,000 units/ml and significant fibrosis	(Metavir Stage F2 or greater or moderate		
and					
and					
and	No continuing alcohol abuse or int	ravenous drug use			
and	Not co-infected with HCV, HIV or F	HDV			
and	Neither ALT nor AST > 10 times u	oper limit of normal			
and	No history of hypersensitivity or contraindications to pegylated interferon				
and	Maximum of 48 weeks therapy				
Initial application — myeloproliferative disorder or cutaneous T cell lymphoma Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)					
or	Patient has a cutaneous T cell lym	phoma*			
	Patient has a myeloprolifera	tive disorder*			
	Patient is intolerant of hydro	xyurea			
	and Treatment with anagrelide a	nd busulfan is not clinically appropriate			
or	or				
	Patient has a myeloprolifera	tive disorder			
	Patient is pregnant, planning	g pregnancy or lactating			

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 4 Form SA2034 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A - continued				
Renewal — myeloproliferative disorder or cuta Current approval Number (if known):	vals valid for 12 months.			
The treatment remains appropriate and patient is benefitting from treatment and Patient has a cutaneous T cell lymphoma*				
or	roliferative disorder* rant of hydroxyurea and treatment with anagrelide and anather than a second and the second	d busulfan remains clinically inappropriate		
Note: Indications marked with * are unapproved in	ndications.			
Initial application — post-allogenic bone marro Applications from any relevant practitioner. Appro Prerequisites(tick box where appropriate) Patient has received an allogeneic bone		pse		
Renewal — post-allogenic bone marrow transp	plant			
Current approval Number (if known):				
Applications from any relevant practitioner. Appro	vals valid for 3 months.			
Prerequisites(tick box where appropriate)				
Patient is responding and ongoing treatr Note: Indications marked with * are unapproved in	nent remains appropriate ndications.			

I confirm the above details are correct and that in signing this form I understand I may be audited.